Search Results for "vol"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vol. Results 81 to 90 of 369 total matches.

Adult Immunization

   
The Medical Letter on Drugs and Therapeutics • Oct 17, 2022  (Issue 1661)
Expanded Table: Some Vaccines for Adults online The Medical Letter ® Vol. 64 (1661) October 17, 2022 162 ...
The Advisory Committee on Immunization Practices (ACIP) recommends use of certain vaccines in adults residing in the US. Routine childhood immunization has reduced the overall incidence of some of these vaccine-preventable diseases, but many adults remain susceptible. Recommendations for vaccination against COVID-19, seasonal influenza, and monkeypox and vaccination of travelers have been reviewed separately.
Med Lett Drugs Ther. 2022 Oct 17;64(1661):161-8 | Show Introduction Hide Introduction

In Brief: Sacubitril/Valsartan (Entresto) Expanded Indication

   
The Medical Letter on Drugs and Therapeutics • May 03, 2021  (Issue 1623)
://medicalletter.org/TML-article-1619e 66 The Medical Letter ® Vol. 63 (1623) May 3, 2021 Medical Letter Entresto ...
The oral fixed-dose combination of the neprilysin inhibitor sacubitril and the angiotensin receptor blocker (ARB) valsartan (Entresto – Novartis) was approved in 2015 to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction (HFrEF; LVEF...
Med Lett Drugs Ther. 2021 May 3;63(1623):65 | Show Introduction Hide Introduction

COVID-19 Update: FDA Narrows EUA for the Johnson & Johnson Vaccine

   
The Medical Letter on Drugs and Therapeutics • Jun 13, 2022  (Issue 1652)
, 2022. The Medical Letter ® Vol. 64 (1652) June 13, 2022 vaccines Spikevax COVID-19 Comirnaty ...
The FDA has restricted its Emergency Use Authorization for the adenovirus-based COVID-19 vaccine manufactured by Johnson & Johnson (Janssen) to adults who are unable or unwilling to receive another COVID-19 vaccine. The mRNA COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) are preferred for all persons without a contraindication.
Med Lett Drugs Ther. 2022 Jun 13;64(1652):94-5 | Show Introduction Hide Introduction

In Brief: Over-the-Counter Narcan Nasal Spray

   
The Medical Letter on Drugs and Therapeutics • May 01, 2023  (Issue 1675)
. The Medical Letter ® Vol. 65 (1675) May 1, 2023 buprenorphine methadone opioid dependence opioid abuse ...
The FDA has approved the over-the-counter (OTC) sale of Narcan (Emergent), a nasal spray that delivers 4 mg of the opioid antagonist naloxone. Narcan nasal spray has been available by prescription since 2015 for emergency treatment of opioid overdose. Generic formulations of Narcan have also been approved; the manufacturers of these products will be required to switch them to OTC status and amend their labeling accordingly. Kloxxado, an 8-mg naloxone nasal spray, remains available only by prescription.
Med Lett Drugs Ther. 2023 May 1;65(1675):72   doi:10.58347/tml.2023.1675e | Show Introduction Hide Introduction

Drugs for Chronic Insomnia

   
The Medical Letter on Drugs and Therapeutics • Jan 09, 2023  (Issue 1667)
of falls. The Medical Letter ® Vol. 65 (1667) January 9, 2023 2 Benzodiazepine receptor agonists ...
Cognitive behavioral therapy for insomnia (CBT-I) is recommended for initial treatment of chronic insomnia. CBT-I includes stimulus control, sleep education and hygiene, sleep restriction, relaxation training, and cognitive therapy. When CBT-I alone is not effective, pharmacologic treatment should be added.
Med Lett Drugs Ther. 2023 Jan 9;65(1667):1-6   doi:10.58347/tml.2023.1667a | Show Introduction Hide Introduction

Treatment of Common Respiratory Tract Infections

   
The Medical Letter on Drugs and Therapeutics • Apr 17, 2023  (Issue 1674)
The Medical Letter ® Vol. 65 (1674) April 17, 2023 58 Table 1. Empiric Treatment of Some Outpatient ...
Most respiratory tract infections are caused by viruses. Bacterial respiratory tract infections are usually treated empirically with antibiotic therapy that targets the most probable causative pathogens. Recommended antibiotic regimens for outpatient treatment of some common respiratory tract infections are listed in Table 1 for adults and Table 2 for children.
Med Lett Drugs Ther. 2023 Apr 17;65(1674):57-62   doi:10.58347/tml.2023.1674a | Show Introduction Hide Introduction

Influenza Vaccine for 2023-2024

   
The Medical Letter on Drugs and Therapeutics • Oct 16, 2023  (Issue 1687)
During the The Medical Letter ® Vol. 65 (1687) October 16, 202 vaccination was associated with a 52 ...
Annual vaccination in the US against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication. Influenza vaccines that are available in the US for the 2023-2024 season are listed in Table 2.
Med Lett Drugs Ther. 2023 Oct 16;65(1687):161-6   doi:10.58347/tml.2023.1687a | Show Introduction Hide Introduction

Drugs for Bipolar Disorder

   
The Medical Letter on Drugs and Therapeutics • Apr 01, 2024  (Issue 1699)
creatinine clearance, have been reported with long-term use of The Medical Letter ® Vol. 66 (1699) April 1 ...
Bipolar disorder is characterized by episodes of mania, hypomania, and depression. Recurrences of manic or (more frequently) depressive symptoms are common. About 15-20% of patients with bipolar disorder die by suicide.
Med Lett Drugs Ther. 2024 Apr 1;66(1699):49-54   doi:10.58347/tml.2024.1699a | Show Introduction Hide Introduction

Drugs for Rheumatoid Arthritis

   
The Medical Letter on Drugs and Therapeutics • Nov 15, 2021  (Issue 1637)
by methotrexate. The Medical Letter ® Vol. 63 (1637) November 15, 2021 Table 1. Some Conventional DMARDs ...
Rheumatoid arthritis (RA) is prevalent in 0.5% of adults in the US; it is about 2.5 times more common in women than in men. Guidelines for treatment of RA from the American College of Rheumatology were recently updated. The goal of treatment is to minimize disease activity and prevent irreversible joint damage.
Med Lett Drugs Ther. 2021 Nov 15;63(1637):177-84 | Show Introduction Hide Introduction

Drugs for GERD and Peptic Ulcer Disease

   
The Medical Letter on Drugs and Therapeutics • Apr 04, 2022  (Issue 1647)
completion of therapy. The Medical Letter ® Vol. 64 (1647) April 4, 2022 50 recommended. PPIs decrease ...
Gastroesophageal reflux disease (GERD) is the most common GI condition encountered in the outpatient setting; it affects about 20% of people in the US.
Med Lett Drugs Ther. 2022 Apr 4;64(1647):49-56 | Show Introduction Hide Introduction